

Richard T Bryan Mbchb

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8547378/richard-t-bryan-mbchb-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119
papers

2,398
citations

30
h-index

46
g-index

136
ext. papers

3,101
ext. citations

4.7
avg, IF

5.02
L-index

#	Paper	IF	Citations
119	Immunotherapy for non-muscle-invasive bladder cancer: from the origins of BCG to novel therapies. <i>Future Oncology</i> , 2022 , 18, 105-115	3.6	0
118	Scoping review: bladder cancer in Nigeria - what are the gaps in clinical care and research?. <i>BMJ Open</i> , 2022 , 12, e049241	3	
117	STAG2 Protein Expression in Non-muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes.. <i>European Urology Open Science</i> , 2022 , 38, 88-95	0.9	1
116	Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer. <i>European Urology Focus</i> , 2021 , 7, 1044-1051	5.1	3
115	Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer. <i>Scandinavian Journal of Urology</i> , 2021 , 1-7	1.6	1
114	The Sirenic Links between Diabetes, Obesity, and Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
113	Establishing the Bladder Cancer Research Centre at the University of Birmingham. <i>Nature Reviews Urology</i> , 2021 , 18, 318-320	5.5	0
112	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. <i>Nature Communications</i> , 2021 , 12, 2301	17.4	24
111	A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection. <i>Bladder Cancer</i> , 2021 , 7, 221-241	1	0
110	Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?. <i>Translational Andrology and Urology</i> , 2021 , 10, 2787-2808	2.3	0
109	The experience of UK patients with bladder cancer during the COVID-19 pandemic: a survey-based snapshot. <i>BJU International</i> , 2021 , 127, 179-181	5.6	1
108	Systematic review of the association between socioeconomic status and bladder cancer survival with hospital type, comorbidities, and treatment delay as mediators.. <i>BJUI Compass</i> , 2021 , 2, 140-158	0.9	0
107	Scoping review protocol: bladder cancer in Nigeria: what are the gaps in clinical care and research?. <i>BMJ Open</i> , 2021 , 11, e041894	3	2
106	PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium. <i>Frontiers in Oncology</i> , 2021 , 11, 626748	5.3	3
105	Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. <i>European Urology</i> , 2021 , 80, 12-15	10.2	9
104	Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2021 , 5, 70-70	6.7	0
103	The need for supportive mental wellbeing interventions in bladder cancer patients: A systematic review of the literature. <i>PLoS ONE</i> , 2021 , 16, e0243136	3.7	1

102	Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience. <i>Inquiry (United States)</i> , 2021 , 58, 469580211030217	1.4	
101	Back-Splicing Transcript Isoforms (Circular RNAs) Affect Biologically Relevant Pathways and Offer an Additional Layer of Information to Stratify NMIBC Patients. <i>Frontiers in Oncology</i> , 2020 , 10, 812	5.3	5
100	Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. <i>Lancet, The</i> , 2020 , 395, 1268-1277	4.0	133
99	The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial. <i>Trials</i> , 2020 , 21, 629	2.8	1
98	Fruit consumption and the risk of bladder cancer: A pooled analysis by the Bladder Cancer Epidemiology and Nutritional Determinants Study. <i>International Journal of Cancer</i> , 2020 , 147, 2091-2100	7.5	8
97	Fluid intake and clinicopathological characteristics of bladder cancer: the West Midlands Bladder Cancer Prognosis Programme. <i>European Journal of Cancer Prevention</i> , 2020 , 29, 110-118	2	
96	A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients. <i>European Urology Oncology</i> , 2020 , 3, 239-249	6.7	30
95	Gene-environment interaction with smoking for increased non-muscle-invasive bladder cancer tumor size. <i>Translational Andrology and Urology</i> , 2020 , 9, 1329-1337	2.3	2
94	Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial. <i>Pilot and Feasibility Studies</i> , 2020 , 6, 165	1.9	1
93	Aryloxy Diester Phosphoramidate Prodrugs of Phosphoantigens (ProPAgens) as Potent Activators of Vβ/Vδ T-Cell Immune Responses. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 11258-11270	8.3	8
92	Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation. <i>European Urology Focus</i> , 2020 , 6, 683-697	5.1	4
91	Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. <i>European Urology</i> , 2019 , 76, 258-259	10.2	15
90	Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. <i>BJU International</i> , 2019 , 124, 532-544	5.6	23
89	Health-related quality of life around the time of diagnosis in patients with bladder cancer. <i>BJU International</i> , 2019 , 124, 984-991	5.6	7
88	Patients choose certainty over burden in bladder cancer surveillance. <i>World Journal of Urology</i> , 2019 , 37, 2747-2753	4	2
87	Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	2
86	Association between treatment of superficial bladder cancer and 10-year mortality in older adults with multiple chronic conditions. <i>Cancer</i> , 2019 , 125, 652	6.4	1
85	Isoform Expression Associated with Outcome Following Radiotherapy in Muscle-Invasive Bladder Cancer does not Alter Cell Survival and DNA Double-Strand Break Repair Following Ionising Radiation. <i>Bladder Cancer</i> , 2019 , 5, 147-157	1	1

84	Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. <i>Eur Urol</i> 2019;76:260-1. <i>European Urology</i> , 2019, 76, e45-e46	10.2	1
83	Asymptomatic Microscopic Haematuria and Significant Urinary Tract Disease. <i>Bladder Cancer</i> , 2019, 5, 115-117	1	0
82	External Replication of Urinary Bladder Cancer Prognostic Polymorphisms in the UK Biobank. <i>Frontiers in Oncology</i> , 2019, 9, 1082	5.3	2
81	Graham Roberts Study protocol: first trials within cohort study for bladder cancer. <i>BMJ Open</i> , 2019, 9, e029468	3	3
80	Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers. <i>Bladder Cancer</i> , 2019, 5, 263-272	1	7
79	Genome-wide Association Study for Tumour Stage, Grade, Size, and Age at Diagnosis of Non-muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2019, 2, 381-389	6.7	5
78	Systematic Review: Genetic Associations for Prognostic Factors of Urinary Bladder Cancer. <i>Biomarkers in Cancer</i> , 2019, 11, 1179299X19897255	7	3
77	Modeling the Complex Exposure History of Smoking in Predicting Bladder Cancer: A Pooled Analysis of 15 Case-Control Studies. <i>Epidemiology</i> , 2019, 30, 458-465	3.1	5
76	Tar, nicotine and carbon monoxide yield of UK cigarettes and the risk of non-muscle-invasive and muscle-invasive bladder cancer. <i>European Journal of Cancer Prevention</i> , 2019, 28, 40-44	2	1
75	Impact of dietary patterns and the main food groups on mortality and recurrence in cancer survivors: a systematic review of current epidemiological literature. <i>BMJ Open</i> , 2018, 8, e014530	3	32
74	HumanMethylation450K Array-Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-muscle Invasive Bladder Cancer. <i>Biomarkers in Cancer</i> , 2018, 10, 1179299X17751920	7.8	8
73	Fruit and vegetable intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort study. <i>Cancer Causes and Control</i> , 2018, 29, 573-579	2.8	6
72	Centralisation of radical cystectomies for bladder cancer in England, a decade on from the Improving Outcomes Guidance the case for super centralisation. <i>BJU International</i> , 2018, 121, 217-224	5.6	34
71	Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours. <i>Scientific Reports</i> , 2018, 8, 11290	4.9	13
70	A Stratified Meta-Analysis of the Association between Exposure to Environmental Tobacco Smoke during Childhood and Adulthood and Urothelial Bladder Cancer Risk. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15,	4.6	5
69	Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 407-407	2.2	50
68	Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification. <i>Oncotarget</i> , 2018, 9, 25244-25253	3.3	10
67	Total Fluid Intake and the Risk of Recurrence in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study. <i>Bladder Cancer</i> , 2018, 4, 303-310	1	2

66	Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the 228 G>A/T Mutation. <i>Bladder Cancer</i> , 2018 , 4, 41-48	1	31
65	The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study. <i>Cancer Causes and Control</i> , 2018 , 29, 675-683	2.8	8
64	Urinary biomarkers for the diagnosis of urothelial bladder cancer. <i>European Journal of Molecular and Clinical Medicine</i> , 2017 , 3, 221	0.7	0
63	UroMark-a urinary biomarker assay for the detection of bladder cancer. <i>Clinical Epigenetics</i> , 2017 , 9, 8	7.7	55
62	Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer. <i>PLoS ONE</i> , 2017 , 12, e0184841	3.7	15
61	Multiplex screening of 422 candidate serum biomarkers in bladder cancer patients identifies syndecan-1 and macrophage colony-stimulating factor 1 as prognostic indicators. <i>Translational Cancer Research</i> , 2017 , 6, S657-S665	0.3	2
60	Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. <i>European Journal of Human Genetics</i> , 2016 , 24, 1167-74	5.3	85
59	The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target. <i>Future Oncology</i> , 2016 , 12, 595-600	3.6	8
58	Significant Role of Lifetime Cigarette Smoking in Worsening Bladder Cancer and Upper Tract Urothelial Carcinoma Prognosis: A Meta-Analysis. <i>Journal of Urology</i> , 2016 , 195, 872-9	2.5	30
57	Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. <i>PLoS ONE</i> , 2016 , 11, e0149756	3.7	52
56	Prediction of histological stage based on cystoscopic appearances of newly diagnosed bladder tumours. <i>Annals of the Royal College of Surgeons of England</i> , 2016 , 98, 547-551	1.4	7
55	A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 301-317	1	63
54	Viscoelastic properties of human bladder tumours. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2016 , 61, 250-257	4.1	26
53	Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer. <i>Epigenetics</i> , 2016 , 11, 237-46	5.7	30
52	Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. <i>International Journal of Epidemiology</i> , 2016 , 45, 857-70	7.8	91
51	The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results. <i>European Urology</i> , 2016 , 70, 506-15	10.2	93
50	Design of an improved surgical instrument for the removal of bladder tumours. <i>Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine</i> , 2016 , 230, 579-87	1.7	1
49	Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM. <i>British Journal of Cancer</i> , 2015 , 112, 1052-8	8.7	31

48	A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. <i>European Urology Focus</i> , 2015 , 1, 82-89	5.1	8
47	Frequency dependent viscoelastic properties of porcine bladder. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2015 , 42, 168-76	4.1	30
46	Diagnosis and treatment of non-muscle-invasive bladder cancer. <i>Trends in Urology & Mens Health</i> , 2015 , 6, 23-27	0.3	2
45	Use of Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer. <i>Proteomes</i> , 2015 , 3, 266-282	4.6	5
44	Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer. <i>PLoS ONE</i> , 2015 , 10, e0137003	3.7	29
43	Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015 , 370, 20140042	5.8	32
42	Words of wisdom. Bladder cancers arise from distinct urothelial sub-populations. <i>European Urology</i> , 2015 , 67, 590-1	10.2	2
41	Words of wisdom. Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. <i>European Urology</i> , 2015 , 67, 591-2	10.2	
40	Urinary EGFR as a marker of urinary bladder cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 327-327	2.2	
39	Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential. <i>British Journal of Cancer</i> , 2014 , 110, 679-85	8.7	31
38	Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guërin. <i>Future Oncology</i> , 2014 , 10, 1443-56	3.6	15
37	The Safe and Economical Care of Ta Bladder Cancer. <i>Urology Practice</i> , 2014 , 1, 176-183	0.8	1
36	Does the nonurologic scientific community understand urothelial bladder cancer?. <i>European Urology</i> , 2014 , 66, 601-2	10.2	4
35	Re: defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. D. Lamm, R. Persad, M. Brausi, R. Buckley, J. A. Witjes, J. Palou, A. Bille, A. M. Kamat, M. Colombel and M. Soloway <i>J Urol</i> 2014;191:20-27. <i>Journal of Urology</i> , 2014 , 191, 1930	2.5	1
34	The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer. <i>Annals of the Royal College of Surgeons of England</i> , 2014 , 96, 415-9	1.4	14
33	Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma. <i>British Journal of Cancer</i> , 2013 , 108, 1854-61	8.7	35
32	Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. <i>European Journal of Cancer</i> , 2013 , 49, 2214-22	7.5	32
31	Update on bladder cancer diagnosis and management. <i>Trends in Urology & Mens Health</i> , 2013 , 4, 7-11	0.3	1

30	Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumors at diagnosis. <i>International Journal of Cancer</i> , 2013 , 133, 446-54	7.5	32
29	A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years. <i>BJU International</i> , 2013 , 112, 169-75	5.6	20
28	Emerging endoscopic and photodynamic techniques for bladder cancer detection and surveillance. <i>Scientific World Journal, The</i> , 2011 , 11, 2550-8	2.2	12
27	Bladder cancer and cancer stem cells: basic science and implications for therapy. <i>Scientific World Journal, The</i> , 2011 , 11, 1187-94	2.2	17
26	Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer. <i>Proteomics - Clinical Applications</i> , 2011 , 5, 493-503	3.1	23
25	Bladder cancer: time for a rethink?. <i>Oncology</i> , 2011 , 25, 965, 968	1.8	3
24	The West Midlands Bladder Cancer Prognosis Programme: rationale and design. <i>BJU International</i> , 2010 , 105, 784-8	5.6	43
23	Biomarkers in bladder cancer. <i>BJU International</i> , 2010 , 105, 608-13	5.6	36
22	Mechanisms of recurrence of Ta/T1 bladder cancer. <i>Annals of the Royal College of Surgeons of England</i> , 2010 , 92, 519-24	1.4	41
21	Narrow-band imaging flexible cystoscopy: a new user experience. <i>Journal of Endourology</i> , 2010 , 24, 1339-43	2.7	35
20	Cadherin switching and bladder cancer. <i>Journal of Urology</i> , 2010 , 184, 423-31	2.5	79
19	Is it time to re-design the haematuria clinic?. <i>BJU International</i> , 2010 , 105, 1478-9; author reply 1479	5.6	
18	Editorial comment on: Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. <i>European Urology</i> , 2010 , 57, 496-7	10.2	
17	Editorial comment on: A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications. <i>European Urology</i> , 2009 , 56, 297	10.2	2
16	Have we abandoned the "superficial" in bladder cancer?. <i>European Urology</i> , 2009 , 56, 1091	10.2	5
15	Re: Palou et al.: Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. (<i>Urology</i> 2009;73:1313-1317). <i>Urology</i> , 2009 , 74, 714	1.6	
14	Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. <i>BJU International</i> , 2008 , 101, 702-5; discussion 705-6	5.6	127
13	Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. <i>Journal of Pathology</i> , 2008 , 215, 184-94	9.4	43

12	Detection of Intestinal Metaplasia in Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2353-2354	0.7	1
11	Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1154-61	0.7	200
10	Molecular pathways in bladder cancer: part 1. <i>BJU International</i> , 2005 , 95, 485-90	5.6	30
9	Molecular pathways in bladder cancer: part 2. <i>BJU International</i> , 2005 , 95, 491-6	5.6	23
8	Socio-economic deprivation and survival in bladder cancer. <i>BJU International</i> , 2004 , 94, 539-43	5.6	14
7	The role of beta-catenin signaling in the malignant potential of cystitis glandularis. <i>Journal of Urology</i> , 2003 , 170, 1892-6	2.5	31
6	Axillary lipoblastoma--tumor recurrence in the right atrium. <i>Journal of Pediatric Surgery</i> , 2003 , 38, 1246-7	2.6	13
5	Delay and survival in bladder cancer. <i>BJU International</i> , 2002 , 89, 868-78	5.6	113
4	Superficial bladder cancer - time to uncouple pT1 tumours from pTa tumours. <i>BJU International</i> , 2002 , 90, 846-52	5.6	32
3	Laparoscopic peritoneal lavage in staging gastric and oesophageal cancer. <i>European Journal of Surgical Oncology</i> , 2001 , 27, 291-7	3.6	23
2	An integrated multi-omics analysis identifies clinically relevant molecular subtypes of non-muscle-invasive bladder cancer		1
1	The experience of UK patients with bladder cancer during the second wave of the COVID-19 pandemic. <i>BJUJ Compass</i> ,	0.9	0